TY  - JOUR 
AU  - Simon, Iris
AU  - Perales Romero, Sonia
AU  - Casado Medina, Laura
AU  - Rodríguez Martínez, Alba
AU  - Garrido Navas, María del Carmen
AU  - Puche Sanz, Ignacio
AU  - Díaz Mochón, Juan José
AU  - Lorente Acosta, José Antonio
AU  - Lupiañez, Pablo
AU  - Serrano, María José
AU  - Real, Pedro J.
PY  - 2021
UR  - http://hdl.handle.net/10481/67961
AB  - Androgen deprivation therapy (ADT) and novel hormonal agents (NHAs) (Abiraterone
and Enzalutamide) are the goal standard for metastatic prostate cancer (PCa) treatment. Although
ADT is initially effective, a subsequent castration resistance status...
LA  - eng
PB  - MDPI
KW  - Castration resistant prostate cancer
KW  - Androgen receptor
KW  - AR-V7
KW  - AR-V9
KW  - Transcriptional regulation
KW  - Novel hormonal agents
KW  - Abiraterone
KW  - Enzalutamide
KW  - Cross-resistance
TI  - Cross-Resistance to Abiraterone and Enzalutamide in Castration Resistance Prostate Cancer Cellular Models Is Mediated by AR Transcriptional Reactivation
DO  - 10.3390/cancers13061483
ER  -